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Abstract: Psoriasis is a common chronic immune-mediated skin disease, with systemic involve-
ment and significant impact in patients’ quality of life. Several highly specific treatments have 
been developed over the years, such as tumor necrosis factor-α inhibitors, a nonselective IL-23 
inhibitor (ustekinumab), and most recently IL-17 inhibitors. Risankizumab is a monoclonal 
antibody which targets IL-23p19 without binding IL-12. This novel therapeutic approach is 
expected to have advantages over the recently approved anti-IL-17 agents, such as the avoidance 
of Candida infections and neutropenia. In addition, unlike ustekinumab, the selective inhibition 
of IL-23 may preserve IL-12-dependent functions such as protection against infections and 
tumor immune surveillance. Risankizumab showed an excellent efficacy when compared to 
placebo and ustekinumab, with higher Psoriasis Area Severity Index (PASI) 75, PASI 90, and 
PASI 100 rates, along with a convenient every 12-week maintenance dosing regimen. Overall, 
risankizumab was well tolerated and the most common adverse event was upper respiratory 
tract infection. In the near future, further data will be available not only in psoriasis but also in 
Crohn’s disease and psoriatic arthritis fields. Head-to-head trials comparing risankizumab with 
other IL-23 inhibitors and with IL-17 inhibitors will be crucial to reveal the role of risankizumab 
in the treatment of psoriasis.
Keywords: psoriasis, IL-23, risankizumab
Introduction
Psoriasis is a common chronic immune-mediated skin disease, with systemic involve-
ment and significant impact in patients’ quality of life,1,2 with a prevalence ranging 
between 1.5% and 5.0% in most developed countries.2
Similar to several immune-mediated inflammatory disorders, psoriasis treat-
ment has evolved immensely. Although conventional treatment is still useful, and 
sometimes enough for some patients, a great proportion of patients will need other 
treatment options, with expected better efficacy and, ultimately, an improvement 
in the quality of life. Over the past decades, our understanding of psoriasis patho-
genesis has significantly expanded, allowing the development of highly specific 
agents, the so-called biologics.3,4 Tumor necrosis factor alpha (TNF-α) inhibitors 
were probably the first major advance in this regard, as significantly higher clinical 
responses were achieved.5,6 However, some patients did not respond to such agents, 
motivating further investigation of additional and possibly more crucial targets. Later, 
ustekinumab, an IL-12/23 inhibitor that selectively targets the common p40 subunit 
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of these cytokines, was developed and not only showed 
promising clinical responses7,8 but also proved to be more 
effective than TNF-α inhibitors.9 Subsequently, as IL-17 
was increasingly becoming a recognized key mediator in the 
pathogenesis of psoriasis, new drugs were developed target-
ing both IL-17 and its receptor (Figure 1).10 These agents 
have been approved to treat moderate to severe psoriasis11–13 
and have been shown to have better clinical responses than 
TNF-α inhibitors14,15 and ustekinumab.12,16,17 In fact, these 
agents introduced a paradigm shift in the management of 
psoriasis, where completely or almost completely clear skin 
has become the new therapeutic goal.18 However, there are 
some class safety concerns. IL-17 inhibitors are associ-
ated with higher risk of mucocutaneous candidiasis and 
neutropenia, reflecting the role of IL-17 in mucocutaneous 
protection against extracellular organisms such as Candida 
albicans and in the granulopoiesis, survival, and activation 
of neutrophils. Nevertheless, these adverse events (AEs) 
tend to be easily manageable and usually do not restrict the 
maintenance of therapy.19,20
Most recently, a new class of highly specific drugs is 
being studied for the treatment of psoriasis – IL-23 inhibitors. 
Risankizumab is a humanized IgG1 monoclonal antibody 
which selectively targets the unique p19 subunit of human 
IL-23.21,22 Indeed, this agent seems to have a similar or higher 
efficacy than IL-17 inhibitors, without the safety concerns 
mentioned above.
This article aims to review the current knowledge on 
risankizumab for the treatment of psoriasis.
Advantages of selective IL-23 
inhibition
Nowadays, it is widely accepted that IL-23/IL-17 axis has a 
crucial role in psoriasis, as in several other immune-mediated 
diseases.23–29 In fact, IL-23 is an essential cytokine for the 
differentiation, maintenance, and activity of several immune 
cells, such as T-helper 17 (Th17) and Th22 cells, and is able to 
induce a self-amplificatory loop by  promoting the  expression 
of additional IL-23 receptors.24,27–29 The first compound 
designed to modulate IL-23/IL-17 axis was ustekinumab – an 
inhibitor of p40 subunit which is shared by two cytokines, 
IL-23 and IL-12.30 Although it proved to be effective,7,8 evi-
dence has suggested a more prominent role of IL-23, when 
comparing to IL-12. Indeed, a predisposition to psoriasis has 
been linked with genes of the IL-23/Th17 axis, but not with 
those of the IL-12/Th1 pathway.31 In addition, inhibition of 
IL-12 may have a negative effect in psoriasis.32 Using the 
imiquimod murine model, IL-12 has been shown to play 
a regulatory role by restraining the infiltration of IL-17A- 
producing γδT cells and inducting a protective transcriptional 
program in keratinocytes, thus limiting skin inflammation.33 
Furthermore, IL-12 has an anti-inflammatory effect through 
induction of expression of IL-10 by Th1 cells, in which 
interferon-γ is a key mediator.34 Importantly, IL-12 has been 
Figure 1 Summarized schematic differences between iL-12/23-p40, iL-23p19, and iL-17 blockade.
Notes: iL-12/23p40 inhibitors, such as ustekinumab, block iL-12 and iL-23 common subunit p40, inhibiting both iL-23/Th17 and iL-12/Th1 pathways; iL-23p19 inhibitors, such 
as risankizumab, guselkumab, and tildrakizumab, selectively block the iL-23/T17 pathway, avoiding effects on the iL-12/Th1 axis; iL-17A inhibitors, such as secukinumab and 
ixekizumab, also target the iL-23/iL-17 axis, although through downstream blockade of this pathway.
Abbreviations: DC, dendritic cell; iNF-γ, interferon gamma; KC, keratinocyte; Th1 and Th17, T-helper cell 1 and 17; TNF-α, tumor necrosis factor alpha.
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implicated in the protection against bacterial and viral infec-
tions35 and may play a role in tumor immune surveillance.36,37
Risankizumab
Risankizumab is a humanized IgG1 monoclonal antibody 
which selectively targets the unique p19 subunit of human 
IL-23 without binding IL-12.21,22
Pharmacokinetics
In a Phase I study,21 after a single intravenous dose of risanki-
zumab, the geometric mean area under the curve (AUC)
0-inf
 
ranged from 2.93 to 1,650 d×μg/mL, while maximum serum 
concentration ranged from 0.311 to 110 μg/mL, increasing 
proportionally with dose. Group mean clearance and termi-
nal phase volume of distribution were 0.33 L/d and 10.8 L, 
respectively. Pharmacokinetic parameter variability was less 
than 50%. The half-life ranged from 20 to 28 days, while 
maximal exposures were reached between days 4 and 10. 
Subcutaneous bioavailability was 59% (ratio of AUC
0-inf
 after 
subcutaneous and intravenous administration). Additionally, 
investigators also stated that the exposure efficacy was com-
parable for intravenous and subcutaneous administrations, 
with maximum PASI responses achievement for doses of 
0.25 mg/kg or greater.
A recent study estimated a clearance, steady-state vol-
ume of distribution, and terminal-phase elimination half-life 
to be ~0.35 L/day, 11.7 L, and 27 days, respectively, for a 
typical 90-kg subject with psoriasis with an albumin level 
of 42 g/L. Risankizumab absolute subcutaneous bioavail-
ability and absorption rate constant were 72% and 0.18 
day−1, respectively. Interindividual variability for clearance 
was 37%.38
Clinical efficacy in psoriasis
Phase i studies
The same Phase I study by Krueger et al also showed effi-
cacy outcomes. At week 12, PASI 75 was achieved in 87%, 
PASI 90 in 58%, and PASI 100 in 16% of the patients, 
whereas none of the patients in the placebo group reached 
any of these clinical responses. At week 24, PASI 75 was 
achieved in 71%, PASI 90 in 48%, and PASI 100 in 29% 
of the patients, compared to 13% for PASI 75 and 0% for 
both PASI 90 and 100 in the placebo group. Additionally, 
for doses of 0.25 mg/kg or greater given intravenously or 
subcutaneously, PASI 75 was achieved in 84%, PASI 90 in 
60%, and PASI 100 in 36%, while among patients receiv-
ing risankizumab subcutaneously, the corresponding PASI 
responses were 100%, 85%, and 54%, respectively. Interest-
ingly, PASI improvements were observed as early as week 2. 
Regarding the Static Physician Global Assessment (sPGA) 
evaluation, results were consistent with PASI scores, as 
all patients getting risankizumab subcutaneously became 
“clear” or “almost clear” at weeks 12 and 24, compared to 
none of patients receiving placebo.21
Phase ii studies
A Phase II, dose-ranging, multicenter, randomized trial by 
Papp et al included 166 patients with moderate to severe 
psoriasis and compared risankizumab with ustekinumab. 
Patients were randomized to receive risankizumab subcuta-
neously (18-mg single dose or 90- or 180-mg doses at weeks 
0, 4, and 16) or ustekinumab (45 or 90 mg, according to body 
weight, at weeks 0, 4, and 16). The primary endpoint was a 
PASI 90 or greater response at week 12. Risankizumab was 
superior to ustekinumab, as 77% of the patients (90 and 180 
mg pooled) achieved the primary endpoint, compared to 40% 
in ustekinumab-treated patients. Additionally, at week 12, 
63%, 98%, and 88% of the patients achieved PASI 75 with 
18-, 90-, and 180-mg doses of risankizumab, respectively, 
compared to 72% in ustekinumab-treated patients. With 
regard to PASI 100, responses of 14%, 41%, and 48% were 
observed in the 18-, 90-, and 180-mg risankizumab groups, 
respectively, compared to 18% in the ustekinumab group. 
sPGA scores of 0 or 1 were observed in 58%, 90%, and 
88% of patients in the 18-, 90-, and 180-mg risankizumab 
groups, respectively, compared to 62% in the ustekinumab 
group. Furthermore, at week 24, the proportion of patients 
who achieved a PASI 75 response was 53%, 90%, and 88% 
for 18-, 90-, and 180-mg dosing regimens of risankizumab, 
respectively, compared with 70% in the ustekinumab group. 
Additionally, at week 24, PASI 90 responses were also 
assessed, with 28%, 63%, and 81% of risankizumab-treated 
patients (18, 90, and 180 mg, respectively), compared to 
55% in the ustekinumab group. Interestingly, improvements 
in PASI score were observed as early as week 2. Clinical 
responses were generally maintained for up to 20 weeks 
after the final dose of risankizumab (week 36), in contrast 
to reduction in clinical responses observed in ustekinumab-
treated patients from week 24. Also, complete clearing 
was maintained in 29% and 26% (90 and 180 mg, respec-
tively) for up to 32 weeks after the final administration of 
risankizumab, whereas no patients had complete clearing 
at 48 weeks in the ustekinumab group. At week 12, 72% of 
patients treated with 90 or 180 mg of risankizumab achieved 
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a Dermatology Life Quality Index (DLQI) score of 0 or 1, 
compared to 53% in the ustekinumab group. Moreover, the 
percentages of patients with DLQI score of 0 or 1 were cor-
related with decreases in PASI and sPGA scores (Table 1).22
In this study, investigators also assessed scalp, fin-
gernail, and palmoplantar disease. At week 12, a mean 
reduction in the Psoriasis Scalp Severity Index of 90% and 
94% (for 90- and 180-mg risankizumab groups, respec-
tively) were observed and sustained over time, compared 
to 82% in the ustekinumab group, with a nonsustained 
response over time. Although fingernail responses were 
slower, a mean reduction in the Nail Psoriasis Severity 
Index (NAPSI) score of 40% was observed at week 12 (for 
both 90- and 180-mg risankizumab groups), increasing to 
61% and 73% for 90- and 180-mg groups, respectively, at 
week 48, compared to 18% decrease in NAPSI score in the 
ustekinumab group.22
Finally, skin biopsy samples were obtained from 60 
patients. Of which, 54% and 69% of the patients in the 
90- and 180-mg risankizumab groups, respectively, had 
global histopathologic assessment graded as “excellent 
improvement,” compared to 29% in the ustekinumab group. 
In addition, patients treated with risankizumab, but not with 
ustekinumab, also had decreased expression of IL-23/IL-17 
axis-related genes.22
Phase iii studies
Recently, two Phase III studies have been published – 
UltIMMa-1 and UltIMMa-2 – and assessed the efficacy and 
safety of risankizumab compared to placebo or ustekinumab 
in patients with moderate to severe plaque psoriasis.39 These 
two studies were replicate Phase III multicenter, randomized, 
double-blind, placebo-controlled, and active comparator-
controlled trials. Patients were randomly assigned (3:1:1; 
506 in UltIMMa-1 and 491 in UltIMMa-2) to receive 
risankizumab, ustekinumab, or placebo, and randomization 
was stratified by weight (≤100 kg vs >100 kg) and previous 
exposure to TNF inhibitor (yes vs no). In part A of the studies 
(16-week  treatment period), patients received either 150 mg 
risankizumab, ustekinumab based on weight per label (45 mg 
for patients with body weight ≤100 kg or 90 mg for patients 
with body weight >100 kg), or placebo subcutaneously at 
weeks 0 and 4. In part B (weeks 16–52), patients originally 
allocated to placebo were switched to 150 mg risankizumab 
at week 16; during this phase, patients received the study drug 
subcutaneously at weeks 16, 28, and 40. Efficacy outcomes 
were assessed at weeks 4, 8, 12, 16, 22, 28, 34, 40, 46, and 
52, and safety was evaluated throughout the study. The co-
primary endpoints were the proportions of patients achieving 
PASI 90 and sPGA 0 or 1 at week 16.39
In both studies, significantly greater proportions of 
patients receiving risankizumab achieved PASI 90 and 
sPGA 0 or 1 at week 16 (P<0.0001 vs placebo). At week 
16, PASI 90 was achieved by 75.3% of patients receiving 
risankizumab compared to 42.0% receiving ustekinumab 
and 4.9% receiving placebo in UltIMMa-1, and by 74.8% of 
patients receiving risankizumab compared to 47.5% receiv-
ing ustekinumab and 2.0% receiving placebo in UltIMMa-2 
(P<0.0001 vs placebo and ustekinumab for both studies). 
sPGA 0 or 1 was achieved by 87.8% of risankizumab-treated 
patients compared to 63.0% of ustekinumab-treated patients 
and 7.8% of placebo-treated patients in UltIMMa-1, and by 
83.7% risankizumab-treated patients compared to 61.6% 
of ustekinumab-treated patients and 5.1% of placebo-
treated patients in UltIMMa-2 (P<0.0001 vs placebo and 
ustekinumab for both studies).39
With regard to complete clearance of psoriatic lesions, 
PASI 100 was achieved by 35.9% of risankizumab-treated 
patients compared to 12.0% of ustekinumab-treated patients 
and none of placebo-treated patients in UltIMMa-1, and 
by 50.7% of patients receiving risankizumab compared 
to 24.2% of patients receiving ustekinumab and 2.0% of 
patients receiving placebo in UltIMMa-2 (P<0.0001 vs 
placebo and ustekinumab for both studies). Furthermore, 
sPGA 0 was achieved by 36.8% of risankizumab-treated 
patients compared to 14.0% of ustekinumab-treated patients 
and 2.0% placebo-treated patients in UltIMMa-1, and by 
51.0% of patients receiving risankizumab compared to 25.3% 
of patients receiving ustekinumab and 3.1% of patients 
receiving placebo in UltIMMa-2 (P<0.0001 vs placebo and 
ustekinumab for both studies).39
Interestingly, significantly higher PASI 90 responses 
were observed starting at week 4 in patients receiv-
ing risankizumab compared to placebo (UltIMMa-1: 
P=0.0001; UltIMMa-2: P<0.0001), and at week 8 com-
pared to ustekinumab (UltIMMa-1 and UltIMMa-2: 
P<0.0001). With regard to sPGA, significantly higher 
proportions of patients treated with risankizumab achieved 
sPGA 0 or 1, starting at week 4, compared to ustekinumab 
(UltIMMa-1: P=0.0047; UltIMMa-2: P=0.0129) and 
placebo (UltIMMa-1 and UltIMMa-2: P<0.0001). Also, 
significantly greater proportions of risankizumab-treated 
patients achieved PASI 75 responses at weeks 12 and 
16 compared to ustekinumab (UltIMMa-1: week 12, 
P=0.0005; week 16, P=0.0034; UltIMMa-2: P<0.0001) 
and placebo (P<0.0001).39
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Additionally, with regard to patient-reported outcomes, 
the proportion of risankizumab-treated patients who achieved 
DLQI 0 or 1 and Psoriasis Symptom Scale (PSS) 0 at week 
16 was significantly higher compared to both ustekinumab 
and placebo groups. In UltIMMa-1, 65.8% of patients 
receiving risankizumab achieved DLQI 0 or 1 compared 
to ustekinumab (43.0%; P<0.0001) and placebo (7.8%; 
P<0.0001); in UltIMMa-2, DLQI 0 or 1 was achieved by 
66.7% of patients receiving risankizumab compared to 46.5% 
of those receiving ustekinumab (P=0.0004) and 4.1% of 
those receiving placebo (P<0.0001). With regard to PSS, at 
week 16, PSS 0 was achieved by 29.3% of patients receiv-
ing risankizumab compared to 15.0% of those receiving 
ustekinumab (P=0.0010) and 2.0% of those receiving placebo 
(P<0.0001) in UltIMMa-1, and by 31.3% of risankizumab-
treated patients compared to 15.2% of ustekinumab-treated 
patients (P=0.0003) and none of placebo-treated patients 
(P<0.0001) in UltIMMa-2.39
After week 16, the proportions of patients achieving 
PASI and sPGA responses continued to increase in patients 
initially assigned to risankizumab. At week 52, PASI 90 was 
achieved by 81.9% of patients on continuous risankizumab 
compared to the ustekinumab group (44.0%) in UltIMMa-1, 
and by 80.6% of patients on continuous risankizumab com-
pared to the ustekinumab group (50.5%) in UltIMMa-2 
(P<0.0001 vs ustekinumab for both studies). At week 52, 
PASI 100 was achieved by 56.3% of patients on continuous 
risankizumab compared to the ustekinumab group (21.0%) 
in UltIMMa-1, and by 59.5% of patients on continuous 
risankizumab compared to the ustekinumab group (30.3%) 
in UltIMMa-2 (P<0.0001 for both studies). sPGA 0 at 
week 52 was achieved by 57.6% of patients on continuous 
risankizumab compared to the ustekinumab group (21.0%) 
in UltIMMa-1, and by 59.5% of patients on continuous 
risankizumab compared to the ustekinumab group (30.3%) 
in UltIMMa-2 (P<0.0001 for both studies). Patients initially 
assigned to placebo switching to risankizumab at week 16 
had similar response rates for PASI, sPGA, DLQI, and PSS 
at week 52 than those initially assigned to risankizumab. 
Finally, among patients who achieved PASI 90 at week 16 
in both studies, a significantly higher proportion of patients 
continuing risankizumab maintained PASI 90 response 
through week 52 compared to the ustekinumab group. At 
week 52, 88.4% of patients on continuous risankizumab 
maintained PASI 90 response compared to 73.3% of patients 
on ustekinumab (P=0.0009) (Table 1).39
The final results of other Phase III studies are awaited, 
comparing risankizumab to adalimumab (IMMvent 
study), secukinumab (NCT03478787), methotrexate 
(NCT03219437), and dimethyl fumarate (NCT03255382); 
assessing the safety and efficacy of risankizumab compared to 
placebo with withdrawal and retreatment (IMMhance study, 
NCT02672852); and assessing the safety and efficacy of 
risankizumab for maintenance in moderate to severe psoriasis 
(LIMMITLESS study, NCT03047395).
Recently, preliminary data from IMMvent (NCT02694523) 
were presented. This was a Phase III randomized, double-
blind, active-controlled study evaluating the efficacy and 
safety of risankizumab compared with adalimumab in adult 
patients with moderate to severe plaque psoriasis. Patients 
were randomized 1:1 to receive 150 mg risankizumab 
(weeks 0, 4, 16, and 28) or adalimumab (80 mg at week 
0, 40 mg every other week from week 1). Adalimumab-
treated patients achieving PASI 50 to < PASI 90 at week 16 
were rerandomized 1:1 to either continue adalimumab or 
switch to risankizumab (weeks 16, 20, and 32). At week 16, 
risankizumab-treated patients achieved significantly higher 
PASI 75 (90.7% vs 71.7%), PASI 90 (72.4% vs 47.4%), PASI 
100 (39.9% vs 23.0%), and sPGA 0/1 (83.7% vs 60.2%) 
response rates compared with adalimumab-treated patients. 
Additionally, among adalimumab-treated patients with PASI 
50 to < PASI 90 responses at week 16, a significantly higher 
proportion of patients switching to risankizumab achieved 
PASI 90 (66.0% vs 21.4%) and PASI 100 (39.6% vs 7.1%) 
responses at week 44 compared with patients continuing 
on adalimumab. Also, PASI 90 and PASI 100 responses 
were significantly higher in patients receiving risankizumab 
starting at week 8 compared with adalimumab. Finally, 
among adalimumab-treated patients achieving PASI 50 to < 
PASI 90 at week 16, PASI 90 and PASI 100 responses were 
significantly higher in patients switching to risankizumab, 
starting at week 20, compared with patients continuing on 
adalimumab.40
Interestingly, a recently presented integrated analy-
sis from Phase III studies UltIMMa-1, UltIMMa-2, and 
IMMhance revealed that the treatment with risankizumab 
was associated with superior efficacy compared with placebo 
regardless of psoriasis treatment history, including prior 
biologic failure.41
Safety and tolerability
The Phase I study by Krueger et al reported similar rates 
(65%) of side effects in both treatment and placebo 
groups. The most common AEs were mild to moderate 
 nasopharyngitis, mild to moderate upper respiratory infec-
tions, and mild to moderate headache. Importantly, none of 
 
P
so
ria
si
s:
 T
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
12
6.
83
.6
 o
n 
11
-M
ar
-2
02
0
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Psoriasis: Targets and Therapy 2018:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
88
Machado and Torres
the serious adverse events (SAEs) verified were considered 
related to risankizumab treatment by investigators.21
The Phase II by Papp et al reported AE rates of 81%, 80%, 
and 69% for the 18-mg, 90-mg, and 180-mg risankizumab 
groups, respectively, and 72% for the ustekinumab group. The 
most common AE in all groups was nasopharyngitis. In the 
18-mg, 90-mg, and 180-mg risankizumab groups, 5 (12%), 6 
(15%), and 0 patient, respectively, had SAEs, including two 
patients with basal cell carcinoma, one patient with myocar-
dial infarction, and one patient who had a cerebrovascular 
accident on the day after elective surgery for preexisting 
cerebral aneurysm.22
In the Phase III studies UltIMMa-1 and UltIMMa-2, 
the AE rates were similar between groups throughout the 
study duration in both studies. The most frequent AEs in 
part A in both studies were viral upper respiratory tract 
infection, upper respiratory tract infection, psoriasis, and 
diarrhea.39 In part A of UltIMMa-1, AEs occurred in 49.7% 
Table 1 Summary of key results from clinical trials of risankizumab
Clinical trial Dosing regimen Proportion of patients achieving
PASI 50 PASI 75 PASI 90 PASI 100 sPGA 0/1 sPGA 0 PSS 0
Phase ii study
(Papp et al22)
18-mg single dose of 
risankizumab at week 0; or 
90-mg or 180-mg doses of 
risankizumab or 45-mg or 
90-mg doses of ustekinumab 
based on weight (≤100 kg vs 
>100 kg), at weeks 0, 4, and 16
At week 12
Risankizumab:
18-mg: 86.0%
90-mg: 100.0%
(P<0.001)
180-mg: 92.9%
Ustekinumab: 82.5%
At week 12
Risankizumab:
18-mg: 62.8%
90-mg: 97.6%
(P<0.001)
180-mg: 88.1%
Ustekinumab: 72.5%
At week 24
Risankizumab:
18-mg: 53.0%
90-mg: 90.0%
180-mg: 88.0%
Ustekinumab: 70.0%
At week 12
Risankizumab:
18-mg: 30.2%
90-mg: 73.2%
(P<0.001)
180-mg: 78.6%
(P<0.001)
Ustekinumab: 40.0%
At week 24
Risankizumab:
18-mg: 28.0%
90-mg: 63.0%
180-mg: 81.0%
Ustekinumab: 55.0%
At week 12
Risankizumab:
18-mg: 13.9%
90-mg: 41.5%
(P<0.001)
180-mg: 47.6%
(P<0.001)
Ustekinumab: 17.5%
At week 12
Risankizumab:
18-mg: 58.1%
90-mg: 90.2%
(P<0.001)
180-mg: 88.1%
(P<0.001)
Ustekinumab: 62.5%
Not reported Not reported
UltiMMa-1 Part A:
150-mg dose of risankizumab, 
45-mg or 90-mg doses of 
ustekinumab based on weight 
(≤100 kg vs >100 kg), or 
placebo, at weeks 0 and 4
Part B:
Patients initially assigned to 
placebo switched to 150 mg 
risankizumab at week 16
Not reported At week 12
Risankizumab: 86.8%
Ustekinumab: 70.0%
(P=0.0005)
Placebo: 9.8%
(P<0.0001)
Placebo to risankizumab: NA
At week 16
Risankizumab: 75.3%
Ustekinumab: 42.0%
(P<0.0001)
Placebo: 4.9%
(P<0.0001)
Placebo to risankizumab: NA
At week 52
Risankizumab: 81.9%
Ustekinumab: 44.0%
(P<0.0001)
Placebo: NA
Placebo to risankizumab: 78.4%
At week 16
Risankizumab: 35.9%
Ustekinumab: 12.0%
(P<0.0001)
Placebo: 0%
(P<0.0001)
Placebo to risankizumab: NA
At week 52
Risankizumab: 56.3%
Ustekinumab: 21.0%
(P<0.0001)
Placebo: NA
Placebo to risankizumab: 54.6%
At week 12
Risankizumab: 82.2%
Ustekinumab: 65.0%
(P=0.0007)
Placebo: 8.8%
(P<0.0001)
Placebo to risankizumab: NA
At week 16
Risankizumab: 87.8%
Ustekinumab: 63.0%
(P<0.0001)
Placebo: 7.8%
(P<0.0001)
Placebo to risankizumab: NA
At week 16
Risankizumab: 36.8%
Ustekinumab: 14.0%
(P<0.0001)
Placebo: 2.0%
(P<0.0001)
Placebo to risankizumab: NA
At week 52
Risankizumab: 57.6%
Ustekinumab: 21.0%
(P<0.0001)
Placebo: NA
Placebo to risankizumab: 54.6%
At week 16
Risankizumab: 29.3%
Ustekinumab: 15.0%
(P=0.0010)
Placebo: 2.0%
(P<0.0001)
Placebo to risankizumab: NA
UltiMMa-2 Not reported At week 12
Risankizumab: 88.8%
Ustekinumab: 69.7%
(P<0.0001)
Placebo: 8.2%
(P<0.0001)
Placebo to risankizumab: NA
At week 16
Risankizumab: 74.8%
Ustekinumab: 47.5%
(P<0.0001)
Placebo: 2.0%
(P<0.0001)
Placebo to risankizumab: NA
At week 52
Risankizumab: 80.6%
Ustekinumab: 50.5%
(P<0.0001)
Placebo: NA
Placebo to risankizumab: 85.1%
At week 16
Risankizumab: 50.7%
Ustekinumab: 24.2%
(P<0.0001)
Placebo: 2.0%
(P<0.0001)
Placebo to risankizumab: NA
At week 52
Risankizumab: 59.5%
Ustekinumab: 30.3%
(P<0.0001)
Placebo: NA
Placebo to risankizumab: 67.0%
At week 12
Risankizumab: 82.3%
Ustekinumab: 64.6%
(P=0.0006)
Placebo: 9.2%
(P<0.0001)
Placebo to risankizumab: NA
At week 16
Risankizumab: 83.7%
Ustekinumab: 61.6%
(P<0.0001)
Placebo: 5.1%
(P<0.0001)
Placebo to risankizumab: NA
At week 16
Risankizumab: 51.0%
Ustekinumab: 25.3%
(P<0.0001)
Placebo: 3.1%
(P<0.0001)
Placebo to risankizumab: NA
At week 52
Risankizumab: 59.5%
Ustekinumab: 30.3%
(P<0.0001)
Placebo: NA
Placebo to risankizumab: 67.0%
At week 16
Risankizumab: 31.3%
Ustekinumab: 15.2%
(P=0.0003)
Placebo: 0%
(P<0.0001)
Placebo to risankizumab: NA
Note: Nonresponder imputation was used to assess binary endpoints missing data.
Abbreviation: NA, not applicable.
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Table 1 Summary of key results from clinical trials of risankizumab
Clinical trial Dosing regimen Proportion of patients achieving
PASI 50 PASI 75 PASI 90 PASI 100 sPGA 0/1 sPGA 0 PSS 0
Phase ii study
(Papp et al22)
18-mg single dose of 
risankizumab at week 0; or 
90-mg or 180-mg doses of 
risankizumab or 45-mg or 
90-mg doses of ustekinumab 
based on weight (≤100 kg vs 
>100 kg), at weeks 0, 4, and 16
At week 12
Risankizumab:
18-mg: 86.0%
90-mg: 100.0%
(P<0.001)
180-mg: 92.9%
Ustekinumab: 82.5%
At week 12
Risankizumab:
18-mg: 62.8%
90-mg: 97.6%
(P<0.001)
180-mg: 88.1%
Ustekinumab: 72.5%
At week 24
Risankizumab:
18-mg: 53.0%
90-mg: 90.0%
180-mg: 88.0%
Ustekinumab: 70.0%
At week 12
Risankizumab:
18-mg: 30.2%
90-mg: 73.2%
(P<0.001)
180-mg: 78.6%
(P<0.001)
Ustekinumab: 40.0%
At week 24
Risankizumab:
18-mg: 28.0%
90-mg: 63.0%
180-mg: 81.0%
Ustekinumab: 55.0%
At week 12
Risankizumab:
18-mg: 13.9%
90-mg: 41.5%
(P<0.001)
180-mg: 47.6%
(P<0.001)
Ustekinumab: 17.5%
At week 12
Risankizumab:
18-mg: 58.1%
90-mg: 90.2%
(P<0.001)
180-mg: 88.1%
(P<0.001)
Ustekinumab: 62.5%
Not reported Not reported
UltiMMa-1 Part A:
150-mg dose of risankizumab, 
45-mg or 90-mg doses of 
ustekinumab based on weight 
(≤100 kg vs >100 kg), or 
placebo, at weeks 0 and 4
Part B:
Patients initially assigned to 
placebo switched to 150 mg 
risankizumab at week 16
Not reported At week 12
Risankizumab: 86.8%
Ustekinumab: 70.0%
(P=0.0005)
Placebo: 9.8%
(P<0.0001)
Placebo to risankizumab: NA
At week 16
Risankizumab: 75.3%
Ustekinumab: 42.0%
(P<0.0001)
Placebo: 4.9%
(P<0.0001)
Placebo to risankizumab: NA
At week 52
Risankizumab: 81.9%
Ustekinumab: 44.0%
(P<0.0001)
Placebo: NA
Placebo to risankizumab: 78.4%
At week 16
Risankizumab: 35.9%
Ustekinumab: 12.0%
(P<0.0001)
Placebo: 0%
(P<0.0001)
Placebo to risankizumab: NA
At week 52
Risankizumab: 56.3%
Ustekinumab: 21.0%
(P<0.0001)
Placebo: NA
Placebo to risankizumab: 54.6%
At week 12
Risankizumab: 82.2%
Ustekinumab: 65.0%
(P=0.0007)
Placebo: 8.8%
(P<0.0001)
Placebo to risankizumab: NA
At week 16
Risankizumab: 87.8%
Ustekinumab: 63.0%
(P<0.0001)
Placebo: 7.8%
(P<0.0001)
Placebo to risankizumab: NA
At week 16
Risankizumab: 36.8%
Ustekinumab: 14.0%
(P<0.0001)
Placebo: 2.0%
(P<0.0001)
Placebo to risankizumab: NA
At week 52
Risankizumab: 57.6%
Ustekinumab: 21.0%
(P<0.0001)
Placebo: NA
Placebo to risankizumab: 54.6%
At week 16
Risankizumab: 29.3%
Ustekinumab: 15.0%
(P=0.0010)
Placebo: 2.0%
(P<0.0001)
Placebo to risankizumab: NA
UltiMMa-2 Not reported At week 12
Risankizumab: 88.8%
Ustekinumab: 69.7%
(P<0.0001)
Placebo: 8.2%
(P<0.0001)
Placebo to risankizumab: NA
At week 16
Risankizumab: 74.8%
Ustekinumab: 47.5%
(P<0.0001)
Placebo: 2.0%
(P<0.0001)
Placebo to risankizumab: NA
At week 52
Risankizumab: 80.6%
Ustekinumab: 50.5%
(P<0.0001)
Placebo: NA
Placebo to risankizumab: 85.1%
At week 16
Risankizumab: 50.7%
Ustekinumab: 24.2%
(P<0.0001)
Placebo: 2.0%
(P<0.0001)
Placebo to risankizumab: NA
At week 52
Risankizumab: 59.5%
Ustekinumab: 30.3%
(P<0.0001)
Placebo: NA
Placebo to risankizumab: 67.0%
At week 12
Risankizumab: 82.3%
Ustekinumab: 64.6%
(P=0.0006)
Placebo: 9.2%
(P<0.0001)
Placebo to risankizumab: NA
At week 16
Risankizumab: 83.7%
Ustekinumab: 61.6%
(P<0.0001)
Placebo: 5.1%
(P<0.0001)
Placebo to risankizumab: NA
At week 16
Risankizumab: 51.0%
Ustekinumab: 25.3%
(P<0.0001)
Placebo: 3.1%
(P<0.0001)
Placebo to risankizumab: NA
At week 52
Risankizumab: 59.5%
Ustekinumab: 30.3%
(P<0.0001)
Placebo: NA
Placebo to risankizumab: 67.0%
At week 16
Risankizumab: 31.3%
Ustekinumab: 15.2%
(P=0.0003)
Placebo: 0%
(P<0.0001)
Placebo to risankizumab: NA
Note: Nonresponder imputation was used to assess binary endpoints missing data.
Abbreviation: NA, not applicable.
of the patients on risankizumab, 50.0% on ustekinumab, 
and 51.0% on placebo, and in part A of UltIMMa-2, 
AEs occurred in 45.6% of the patients on risankizumab, 
53.5% on ustekinumab, and 45.9% on placebo. SAEs were 
reported in 2.3% of risankizumab-treated patients, 8.0% of 
ustekinumab-treated patients, and 2.9% of placebo-treated 
patients in UltIMMa-1, and in 2.0% of risankizumab-treated 
patients, 3.0% of ustekinumab-treated patients, and 1.0% of 
placebo-treated patients in UltIMMa-2. Serious infections 
occurred in 0.3% in the risankizumab group and 3.0% in 
the ustekinumab group in UltIMMa-1, and in 1.0% in both 
risankizumab and ustekinumab groups in UltIMMa-2. In 
part B, the most frequent AEs were viral upper respiratory 
tract infection, upper respiratory tract infection, urinary tract 
infection, influenza, and headache in both studies. In part B of 
UltIMMa-1, AEs occurred in 61.3% of the patients continu-
ing on risankizumab, 66.7% on ustekinumab, and 67.0% of 
the patients switching from placebo to risankizumab, while in 
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part B of UltIMMa-2, AEs occurred in 55.7% of the patients 
continuing on risankizumab, 74.5% on ustekinumab, and 
64.9% of the patients continuing on risankizumab. SAEs 
were reported in 5.4% of risankizumab-treated patients, 4.0% 
of ustekinumab-treated patients, and 3.1% of the patients 
continuing on risankizumab in UltIMMa-1, and in 4.5% of 
risankizumab-treated patients, 4.3% of ustekinumab-treated 
patients, and 3.2% of the patients continuing on risankizumab 
in UltIMMa-2. During part B, serious infections occurred 
in 0.7% of the patients on risankizumab in both UltIMMa-1 
and UltIMMa-2, and in 1.0% of the patients switching from 
placebo to risankizumab and ustekinumab in UltIMMa-2. In 
part A, malignancy was reported in two patients on risanki-
zumab (squamous cell carcinoma in UltIMMa-1; basal cell 
carcinoma in UltIMMa-2) and in one patient in the placebo 
group (squamous cell carcinoma in UltIMMa-1). Of note, 
there were no events of tuberculosis, opportunistic infections, 
major adverse cardiovascular events (MACEs), or serious 
hypersensitivity across both studies. During part B, two cases 
of latent tuberculosis were reported in the risankizumab treat-
ment group. Through week 52, two patients on risankizumab 
had MACEs, including one patient with cardiovascular 
death and one patient with type 1 myocardial infarction. 
Malignancy was reported in one patient on continuous 
risankizumab (basal cell carcinoma in UltIMMa-2), in one 
patient on ustekinumab (prostate cancer in UltIMMa-2), and 
in two patients switching from placebo to risankizumab (one 
patient with both basal cell and squamous cell carcinoma in 
UltIMMa-1; one patient with breast cancer in UltIMMa-2).39
immunogenicity
Krueger et al reported anti-drug antibodies in 15% of the 
patients, although no association with loss of efficacy was 
noted.21 A similar incidence was reported by Papp et al (14% 
of patients); in most patients antibodies were transient and 
with low titers, or both; also, three patients had neutralizing 
anti-drug antibodies.22
Discussion
The IL-23/IL-17 axis is currently considered to be essential 
in the pathogenesis of psoriasis. Laboratory studies have 
identified this axis as the primary signaling pathway leading 
to characteristic molecular, cellular, and structural changes 
in psoriatic skin.3,29,42,43 The critical importance of the IL-23/
T17 axis in psoriasis is highlighted by the high efficacy and 
rapid onset of action seen with IL-17 antagonists and most 
recently with IL-23 antagonists.29 However, anti-IL-23 agents 
may provide equal or higher clinical efficacy of anti-IL-17 
agents, without the AEs of the latter, namely mucocutaneous 
candidiasis and neutropenia.19,20
After the recent approval of guselkumab for the treatment 
of moderate to severe plaque psoriasis,44 risankizumab may be 
the next agent in the class to enter the market after showing 
excellent results in Phase II and Phase III trials in comparison 
to both placebo and ustekinumab,22,39 a standard of treatment 
for most psoriatic patients under biological treatment, while 
offering a similar every 12-week maintenance dosing regi-
men as ustekinumab, known for its high convenience of use. 
Additionally, risankizumab has shown response rates signifi-
cantly higher than those seen with TNF-α45 and numerically 
superior than those of IL-17 inhibitors.46,47
The selective inhibition of IL-23 may present several 
advantages compared to the inhibition of p40 subunit 
shared by IL-23 and IL-12 and even a downstream inhibi-
tion of IL-17 or its receptor. Early clinical studies showed 
relatively long-term treatment responses in some patients 
with just a single doses of IL-23p19 inhibition.21,48 The 
explanation behind this impressive clinical response may 
rely in part by promoting transdifferentiation of Th17 
cells into regulatory T cell or Th1 populations.49,50 Also, 
risankizumab maintained high FoxP3 mRNA levels in 
posttreatment lesional skin, indicating that it may increase 
regulatory T-cell levels or function in resolved psoriatic 
lesions.21 Other cytokines may similarly be affected with 
the inhibition of p19 subunit, besides IL-23, such as IL-39, 
a recently discovered proinflammatory cytokine likely 
expressed in psoriatic skin.43,51 Additionally, blockade of 
IL-23 through the inhibition of the p19 subunit would 
also allow IL-12 and IL-Y to maintain their beneficial 
anti-inflammatory effects on T17-centered inflamma-
tion in the skin.43 Indeed, IL-12 has limited to no role in 
psoriasis and its inhibition may have a negative effect in 
psoriasis, as IL-12 has been shown to play a regulatory 
role by preventing the infiltration of IL-17A-producing 
γδT-cells, therefore limiting skin inflammation.33 Notably, 
IL-12 has been implicated in the protection against intracel-
lular pathogens5,35,52 and may play a role in tumor immune 
surveillance.36,37
Overall, risankizumab showed a similar safety and toler-
ability profile compared to ustekinumab and placebo.22,39 Two 
major MACEs were reported in the risankizumab treatment 
group of UltIMMa-2, but both patients had several cardio-
vascular risk factors and the events were not considered to 
be related to the study drug.39 Additionally, although MACEs 
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have been associated with the use of anti-IL-12/23p40 agents 
(ustekinumab and briakinumab) in patients with psoriasis, the 
5-year long-term safety data of ustekinumab and the Psoriasis 
Longitudinal Assessment and Registry (PSOLAR) data have 
shown neither increase nor decrease in the rate of MACEs 
over time,53,54 and so far there seems to be no increased risk 
of MACEs with risankizumab. Nevertheless, future studies 
with more patients and longer follow-up periods will help 
establish a more complete safety profile.
Multiple studies comparing risankizumab to adali-
mumab or secukinumab are ongoing, not only in pso-
riasis but also in Crohn’s disease (NCT03105102, 
NCT03105128, NCT03104413, NCT02513459) and psori-
atic arthritis (NCT02719171, NCT02986373, NCT03671148, 
NCT03675308). In fact, promising preliminary results were 
observed regarding the use of risankizumab in Crohn’s 
disease.55–57
Altogether, psoriasis, once a difficult-to-treat disease, 
represents now a success in terms of clinical efficacy due 
to the highly specific treatments we have nowadays. In fact, 
the high efficacy of these novel agents has established very 
high primary study end points used in clinical trials, as PASI 
90 is now regarded as the new treatment standard,3,18,29 and 
in some patients, long-term remission of psoriasis activity 
may be a possibility. However, some psoriatic patients do 
not improve or just respond partially with IL-17 or IL-23 
blockade, highlighting the complexity of the disease and 
motivating further investigation to fully understand what is 
behind the skin of our patients.
Conclusion
Risankizumab is a monoclonal antibody that selectively 
targets IL-23, offering remarkable rates of complete or near 
complete clearance of skin disease, along with a good safety 
profile so far and an excellent dosing regimen. Data from 
clinical trials comparing risankizumab with other IL-23 and 
IL-17 inhibitors will be essential to establish the value of 
risankizumab in the treatment of psoriasis.
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